D. Rusalov

发表

Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.

Larry R. Smith, A. Rolland, M. Ye, 2009, Vaccine.

Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses.

D. Doolan, W. Rogers, M. Ferrari, 2010, Vaccine.

Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge

Larry R. Smith, D. Kaslow, A. Rolland, 2007, Human vaccines.

Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes.

M. Ferrari, C. Wheeler, D. Rusalov, 2002, Nucleic acids research.

Trends in lipoplex physical properties dependent on cationic lipid structure, vehicle and complexation procedure do not correlate with biological activity.

M. Ferrari, C. Wheeler, D. Rusalov, 2001, Nucleic acids research.

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

Larry R. Smith, R. Webby, D. Kaslow, 2008, The Journal of infectious diseases.

Physical characterization and in vivo evaluation of poloxamer‐based DNA vaccine formulations

A. Nanci, A. Rolland, Ji-Hyun Yi, 2008, The journal of gene medicine.

First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults

Larry R. Smith, S. Sullivan, M. Mammen, 2019, Antimicrobial Agents and Chemotherapy.

Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus

Larry R. Smith, A. Rolland, S. Sullivan, 2012, Human vaccines & immunotherapeutics.

Comparison of Rabbit and Mouse Models for Persistence Analysis of Plasmid-Based Vaccines

D. Kaslow, A. Rolland, J. Hartikka, 2006, Human vaccines.

Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.

A. Rolland, S. Sullivan, J. Doukas, 2011, Vaccine.

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

Larry R. Smith, R. Moss, R. Steigbigel, 2010, Vaccine.

I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.

D. Kaslow, A. Rolland, J. Hartikka, 2005, Human gene therapy.

Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge.

D. Kaslow, A. Rolland, M. Manthorpe, 2007, Human gene therapy.

II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.

D. Kaslow, A. Rolland, J. Hartikka, 2005, Human gene therapy.

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

D. Kaslow, D. Galloway, P. Hobart, 2004, Proceedings of the National Academy of Sciences of the United States of America.